10x Genomics, Inc. (TXG) intrinsic value & 10-year financials
10x Genomics, Inc. (TXG) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 31.7% a year to $642.8M, with an average return on invested capital of -83.4%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $69.86
- Market cap
- $8.7B
- Revenue (FY2025)
- $642.8M
- Revenue growth (10-yr CAGR)
- 31.7%
- ROIC (10-yr avg)
- -83.4%
- Free cash flow (FY2025)
- $130.1M
TXG 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $642.8M | -$43.5M | -$0.35 | $130.1M | -9.5% | -14.6% |
| FY2024 | $610.8M | -$182.6M | -$1.52 | -$5.7M | -31.9% | -43.0% |
| FY2023 | $618.7M | -$255.1M | -$2.18 | -$63.8M | -42.9% | -46.6% |
| FY2022 | $516.4M | -$166.0M | -$1.46 | -$165.3M | -32.5% | -34.3% |
| FY2021 | $490.5M | -$58.2M | -$0.53 | -$122.7M | -10.7% | -23.8% |
| FY2020 | $298.8M | -$542.7M | -$5.37 | -$254.6M | -178.7% | -675.5% |
| FY2019 | $245.9M | -$31.3M | -$0.80 | -$8.1M | -12.4% | 26.6% |
| FY2018 | $146.3M | -$112.5M | — | -$82.7M | -75.7% | 43.4% |
| FY2017 | $71.1M | -$18.8M | — | -$14.5M | -25.8% | 17.6% |
| FY2016 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
10x Genomics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
10x Genomics, Inc. has historically struggled to out-earn its cost of capital, averaging just -9.1% ROIC.
10x Genomics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, 10x Genomics, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-11.63 per share.